Narrow-band ultraviolet therapy in early-stage mycosis fungoides: Study on 20 patients

Valeria Brazzelli, M. Antoninetti, S. Palazzini, F. Prestinari, G. Borroni

Research output: Contribution to journalArticlepeer-review


Background: In recent years, narrow-band ultraviolet B (NB-UVB, 311-313 nm) has been found to be beneficial for early-stages mycosis fungoides (MF). The aim of this study is to investigate the effect of NB-UVB in 20 patients with early-stage MF. Methods: Twenty patients (10 women and 10 men, mean age 54 ± 22 years) with clinically and histologically confirmed MF were enrolled in the study. All of the patients had clinical stage I disease (T1 or T2, N0, M0) with cutaneous involvement, consisting of patch-stage disease of limited extent, in 50% of the cases (stage IA), and more widespread in the other 50% (stage IB). All the patients were treated with NB-UVB therapy until more than 95% clearance of the patient's skin lesions had occurred. Results: A complete response was achieved in 90% of the cases after a mean of 29 ± 14 treatments within a mean period of 4 months (range 1-8 months), with an average cumulative dose of 25 ± 16.77 J/cm2. In the follow-up period, relapse occurred after a mean period of 8 months (range 3-17 months), and then therapy was restarted. Conclusion: This study provides evidence that NB-UVB might be an efficient option for stage IA and IB MF patients.

Original languageEnglish
Pages (from-to)229-233
Number of pages5
JournalPhotodermatology Photoimmunology and Photomedicine
Issue number6
Publication statusPublished - Dec 2007


  • Cutaneous T-cell lymphoma
  • Mycosis fungoides
  • Narrow-band UVB therapy
  • Rebound
  • Remission

ASJC Scopus subject areas

  • Immunology
  • Dermatology


Dive into the research topics of 'Narrow-band ultraviolet therapy in early-stage mycosis fungoides: Study on 20 patients'. Together they form a unique fingerprint.

Cite this